The global molecular cloning market size is calculated at USD 5.53 billion in 2025 and is expected to reach around USD 8.89 billion by 2034, growing at a CAGR of 5.4% for the forecasted period.
Ottawa, Nov. 12, 2025 (GLOBE NEWSWIRE) — The global molecular cloning market size was valued at USD 5.25 billion in 2024 and is predicted to hit around USD 8.89 billion by 2034, rising at a 5.4% CAGR, a study published by Towards Healthcare a sister firm of Precedence Research. The global molecular cloning market is driven by its expanding healthcare applications and growing innovations.
The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/5545
Key Takeaways
- North America held a major revenue share of the market in 2024.
- Asia Pacific is expected to witness the fastest growth in the molecular cloning market during the forecast period.
- By technique, the polymerase chain reaction segment held a major revenue share of the market in 2024.
- By technique, the recombinant DNA technology segment is expected to witness significant growth in the market during the forecast period.
- By application, the therapeutics segment held a major revenue share of the market in 2024.
- By application, the genetic engineering segment is expected to witness significant growth in the market during the forecast period.
- By product, the enzymes segment held a major revenue share of the market in 2024.
- By product, the cloning kits segment is expected to witness significant growth in the market during the forecast period.
- By end user, the academic research institutions segment held a major revenue share of the global molecular cloning market in 2024.
- By end user, the contract research organizations segment is expected to witness significant growth in the market during the forecast period.
What is Molecular Cloning?
The molecular cloning market is driven by growing demand for personalized medicine, gene therapies, and advances in genetic engineering. Molecular cloning refers to the use of laboratory techniques to develop multiple copies of a specific DNA fragment. They are used for the development of protein, gene therapy, vaccines, diagnostic tools, personalized medicines, as well as for genetic engineering and gene function studies.
You can place an order or ask any questions, please feel free to contact us at [email protected]
What are the Major Growth Drivers in the Molecular Cloning Market?
The growing diseases are the major drivers in the market. This is increasing the demand for vaccinations, gene therapies, personalized medicines, and recombinant drugs, which is enhancing the demand for molecular cloning. Additionally, growing R&D investments, outsourcing trends, expanding industries, and technological advancements are other market drivers.
What are the Key Drifts in the Molecular Cloning Market?
The market has been expanding due to the growing collaborations to launch and enhance the use of various molecular cloning techniques.
- In April 2025, a collaboration between Molecular Genetics Core and Oxford Nanopore Technologies was announced for enhancing the availability of PromethION 24 of Oxford Nanopore. Thus, to tackle complex genomics challenges, advanced, real-time, long-read sequencing services will be offered through this collaboration.
- In April 2025, to accelerate clinical adoption of next-generation sequencing tests, a collaboration between Illumina Inc. and Tempus AI, Inc. was announced. The AI technologies of Illumina and the multimodal data platform of Tempus will be combined to enhance genomic algorithms and clinical adoption of molecular testing for patients.
What is the Significant Challenge in the Molecular Cloning Market?
High cost acts as the major challenge in the market. Molecular cloning requires advanced equipment and reagents, which are often expensive, limiting the adoption by startups and smaller labs. Moreover, technical complexities, contamination risk, limited infrastructure, and regulatory challenges are the other market limitations.
Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting
Regional Analysis
Why did North America Dominate the Molecular Cloning Market in 2024?
In 2024, North America captured the biggest revenue share in the market, due to the presence of advanced industries, which contributed to the increased use of molecular cloning for genetic research and drug discoveries. At the same time, the growth in the R&D activities supported by funding and investments accelerated their adoption rates. The industries also contributed to this market growth by developing advanced tools and techniques to enhance molecular cloning workflows. Additionally, the growth in the demand for personalized medicine also contributed to the market growth.
What Made the Asia Pacific Show the Fastest Growth in the Molecular Cloning Market in 2024?
Asia Pacific is expected to host the fastest-growing cannabidiol market during the forecast period, due to expanding industries, which are increasing the production of vaccines, biosimilars, and biopharmaceuticals, and increasing the demand for molecular cloning technologies. Moreover, the growing diseases and R&D are increasing their use in labs, industries, and institutions. Thus, all these advancements with government support and growing collaborations are promoting the market growth.
Segmental Insights
By technique analysis
Why Did the Polymerase Chain Reaction Segment Dominate in the Molecular Cloning Market in 2024?
By technique, the polymerase chain reaction segment held the largest share of the market in 2024, due to its high sensitivity. At the same time, they can develop millions of DNA copies in a few hours, which enhances their adaptation rates. Additionally, their specificity increases their use in various applications.
By technique, the recombinant DNA technology segment is expected to grow significantly in the market during the predicted time, driven by growth in R&D activities. This, in turn, is increasing their use in the development of vaccines, antibodies, gene therapies, as well as genetically modified organisms. Moreover, government funding is enhancing their adoption rates.
By application analysis
Get the latest insights on life science industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership
What Made Therapeutics the Dominant Segment in the Molecular Cloning Market in 2024?
By application, the therapeutics segment led the market in 2024, due to its increased use in the development of vaccines and recombinant proteins. The growth in the diseases also enhanced their use. Moreover, the rise in the demand for personalized medicine has also increased its utilization.
By application, the genetic engineering segment is expected to show lucrative growth in the market during the predicted time, due to growing innovations. Different types of genetic tools, along with the integration of AI, are increasing their use for R&D. Thus, their growing applications and expanding industries are increasing their use.
By product analysis
Which Product Type Segment Held the Dominating Share of the Molecular Cloning Market in 2024?
By product, the enzymes segment held the dominating share of the market in 2024, as they were essential for various core processes. This, in turn, increased their continuous use across various areas. At the same time, the growth in R&D, technological innovations, and their easy scalability increased their adoption rates across the industries.
By product, the cloning kits segment is expected to grow significantly in the market during the upcoming years, driven by their easy use and time-saving approach. They also provide high efficiency and consistent outcomes. This, in turn, is driving their demand in industries, institutes, and labs.
By end-user analysis
How did the Academic Research Institutions Segment Dominated the Molecular Cloning Market in 2024?
By end user, the academic research institutions segment led the global molecular cloning market in 2024, due to their high volume of experiments. Moreover, the growth in the R&D and training programs also increased their use. Additionally, the growth in government funding and investments also enhanced their adoption rates.
By end user, the contract research organizations segment is expected to show lucrative growth in the market during the upcoming years, due to their specialized services and expertise. They provided advanced molecular cloning capabilities and reduced the operational expenses. Furthermore, the growing outsourcing trend is also leading to new collaborations.
Browse More Insights of Towards Healthcare:
The global molecular spectroscopy market was valued at USD 6.97 billion in 2024, increased to USD 7.15 billion in 2025, and is projected to reach approximately USD 9.04 billion by 2034, reflecting a steady CAGR of 2.64% between 2025 and 2034.
The molecular cytogenetics market was valued at USD 2.51 billion in 2024, grew to USD 2.78 billion in 2025, and is anticipated to reach nearly USD 6.9 billion by 2034, expanding at a robust CAGR of 10.64% from 2024 to 2034.
The molecular diagnostics market is projected to grow from USD 17.1 billion in 2025 to about USD 27.21 billion by 2034, advancing at a CAGR of 5.3% during the forecast period (2025–2034).
The molecular interaction analyzer market was estimated at USD 300 million in 2023 and is expected to reach USD 575.4 million by 2034, rising at a CAGR of 6.1% from 2024 to 2034.
The U.S. oncology molecular diagnostics market was valued at USD 810 million in 2024, rose to USD 909.14 million in 2025, and is projected to attain USD 2.57 billion by 2034, registering a strong CAGR of 12.24% between 2025 and 2034.
The core clinical molecular diagnostics market was estimated at USD 5.3 billion in 2023 and is anticipated to reach USD 14.45 billion by 2034, growing at a CAGR of 9.54% from 2024 to 2034.
The global oncology molecular diagnostics market stood at USD 3.11 billion in 2024, increased to USD 3.48 billion in 2025, and is expected to reach around USD 9.76 billion by 2034, expanding at a CAGR of 12.13% between 2025 and 2034.
The global point-of-care molecular diagnostics market was valued at USD 4.05 billion in 2024, grew to USD 4.48 billion in 2025, and is projected to reach approximately USD 11.03 billion by 2034, with a CAGR of 10.45% during 2025–2034.
Recent Developments in the Molecular Cloning Market
- In February 2025, expanded global access to high-quality, low-cost DNA sequencing was announced by Ultima Genomics, Inc., where these DNA sequencing services will provide applications like single-cell sequencing, whole genome sequencing, proteomics, spatial transcriptomics, etc, with the use of UG 100.
- In February 2025, a new category of next-generation sequencing was revealed by Roche with the launch of its proprietary, breakthrough sequencing by expansion (SBX) technology.
- In February 2025, the largest portfolio of omics solutions, such as genomics, single-cell analysis, spatial transcriptomics, etc, and sequencing applications was unveiled by Illumina, Inc.
Molecular Cloning Market Key Players List
- Clontech Laboratories
- Thermo Fisher Scientific
- Qiagen
- Sigma-Aldrich
- Biotechnology Company
- Agilent Technologies
- Addgene
- New England Biolabs
- Illumina
- Sangamo Therapeutics
- Takara Bio
- Merck KGaA
- Genscript
- Promega Corporation
Segments Covered in The Report
By Technique
- Restriction Fragment Length Polymorphism
- Polymerase Chain Reaction
- Recombinant DNA Technology
- DNA Sequencing
- Gel Electrophoresis
By Application
- Therapeutics
- Genetic Engineering
- Agricultural Biotechnology
- Synthetic Biology
By Product
- Enzymes
- Vector Systems
- Cloning Kits
- Competent Cells
By End User
- Academic Research Institutions
- Pharmaceutical Companies
- Biotechnology Companies
- Contract Research Organizations
By Region
North America
- U.S.
- Canada
- Mexico
- Rest of North America
South America
- Brazil
- Argentina
- Rest of South America
Europe
- Western Europe
- Germany
- Italy
- France
- Netherlands
- Spain
- Portugal
- Belgium
- Ireland
- UK
- Iceland
- Switzerland
- Poland
- Rest of Western Europe
- Eastern Europe
- Austria
- Russia & Belarus
- Türkiye
- Albania
- Rest of Eastern Europe
Asia Pacific
- China
- Taiwan
- India
- Japan
- Australia and New Zealand,
- ASEAN Countries (Singapore, Malaysia)
- South Korea
- Rest of APAC
MEA
- GCC Countries
- Saudi Arabia
- United Arab Emirates (UAE)
- Qatar
- Kuwait
- Oman
- Bahrain
- South Africa
- Egypt
- Rest of MEA
Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/checkout/5545
Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Europe Region: +44 778 256 0738
North America Region: +1 8044 4193 44
APAC Region: +91 9356 9282 04
Web: https://www.towardshealthcare.com
Our Trusted Data Partners
Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.